{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:33:44Z","timestamp":1789353224061,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.eururo.2012.09.008","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T01:00:19Z","timestamp":1347498019000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"63","author":[{"given":"Christopher C.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pascoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Chodacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep R.","family":"Germ\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Gillies","family":"O\u2019Bryan-Tear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.09.008_bib0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1006106209527","article-title":"Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone","volume":"17","author":"Lange","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.eururo.2012.09.008_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences, and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2012.09.008_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/pcan.2009.50","article-title":"Bone health and prostate cancer","volume":"13","author":"Saylor","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2012.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.0.CO;2-X","article-title":"Bisphosphonates in prostate carcinoma","volume":"80","author":"Adami","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.09.008_bib0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/srao.2000.6592","article-title":"Systemic radiopharmaceutical therapy of painful osteoblastic metastases","volume":"10","author":"Silberstein","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.eururo.2012.09.008_bib0030","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.008_bib0035","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2012.09.008_bib0040","first-page":"1346","article-title":"Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer","volume":"10","author":"Liepe","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.eururo.2012.09.008_bib0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s002590050306","article-title":"Radioimmunotherapy with alpha-emitting nuclides","volume":"25","author":"McDevitt","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.eururo.2012.09.008_bib0050","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2012.09.008_bib0055","first-page":"38S","article-title":"Bone-seeking radionuclides for therapy","volume":"46","author":"Lewington","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2012.09.008_bib0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(02)00835-5","article-title":"(223)Ra targets skeletal metastases and spares normal tissue","volume":"3","author":"Kerr","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2012.09.008_bib0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/14737140.4.3.459","article-title":"Targeted alpha-therapy for control of micrometastatic prostate cancer","volume":"4","author":"Li","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eururo.2012.09.008_bib0070","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2012.09.008_bib0075","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.09.008_bib0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2012.09.008_bib0085","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.09.008_bib0090","doi-asserted-by":"crossref","unstructured":"Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract E16-2669]. Presented at: European Multidisciplinary Cancer Congress; September 23\u201327, 2011; Stockholm, Sweden.","DOI":"10.1016\/S0959-8049(11)70100-9"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2012.09.008_bib0095","first-page":"411","article-title":"Alpha-emitting radium-223: two years follow-up from a randomized phase II study in patients with bone metastases from hormone-refractory prostate cancer [abstract P-7018]","author":"Nilsson","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.09.008_bib0100","unstructured":"FDA public workshop on clinical trial endpoints in prostate cancer; June 21\u201322, 2004\u2014Bethesda, Maryland. US Food and Drug Administration Web site. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4095B1_03_02-FDA-Tab2.pdf."},{"key":"10.1016\/j.eururo.2012.09.008_bib0105","unstructured":"Palliative care: symptom management and end-of-life care. World Health Organization Web site. http:\/\/www.who.int\/3by5\/publications\/documents\/en\/genericpalliativecare082004.pdf."},{"key":"10.1016\/j.eururo.2012.09.008_bib0110","series-title":"Encyclopedia of statistical sciences","first-page":"315","article-title":"Jonckheere tests for ordered alternatives","author":"Pirie","year":"1983"},{"key":"10.1016\/j.eururo.2012.09.008_bib0115","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.09.008_bib0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urolonc.2010.07.002","article-title":"Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy","volume":"30","author":"Sonpavde","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.09.008_bib0125","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.008_bib0130","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1634\/theoncologist.2009-0043","article-title":"Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature","volume":"14","author":"Armstrong","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2012.09.008_bib0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812010317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812010317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:03:50Z","timestamp":1759583030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812010317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0302283812010317"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.09.008","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958957.793463459","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}